ACAD
Price
$17.14
Change
-$0.06 (-0.35%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
2.88B
77 days until earnings call
EPRX
Price
$3.94
Change
+$0.07 (+1.81%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
136.41M
86 days until earnings call
Ad is loading...

ACAD vs EPRX

Header iconACAD vs EPRX Comparison
Open Charts ACAD vs EPRXBanner chart's image
ACADIA Pharmaceuticals
Price$17.14
Change-$0.06 (-0.35%)
Volume$19.27K
Capitalization2.88B
Eupraxia Pharmaceuticals
Price$3.94
Change+$0.07 (+1.81%)
Volume$100
Capitalization136.41M
ACAD vs EPRX Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. EPRX commentary
May 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a StrongBuy and EPRX is a Hold.

Ad is loading...
COMPARISON
Comparison
May 15, 2025
Stock price -- (ACAD: $17.20 vs. EPRX: $3.87)
Brand notoriety: ACAD and EPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 75% vs. EPRX: 168%
Market capitalization -- ACAD: $2.88B vs. EPRX: $136.41M
ACAD [@Biotechnology] is valued at $2.88B. EPRX’s [@Biotechnology] market capitalization is $136.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $295.2B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileEPRX’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • EPRX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than EPRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while EPRX’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 5 bearish.
  • EPRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EPRX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а +18.29% price change this week, while EPRX (@Biotechnology) price change was -4.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.93%. For the same industry, the average monthly price growth was +6.80%, and the average quarterly price growth was -5.97%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

EPRX is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+0.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.88B) has a higher market cap than EPRX($136M). EPRX YTD gains are higher at: 22.082 vs. ACAD (-6.267). ACAD has higher annual earnings (EBITDA): 102M vs. EPRX (-25.89M). ACAD has more cash in the bank: 682M vs. EPRX (27.5M). EPRX has less debt than ACAD: EPRX (52.8K) vs ACAD (56M). ACAD has higher revenues than EPRX: ACAD (996M) vs EPRX (0).
ACADEPRXACAD / EPRX
Capitalization2.88B136M2,117%
EBITDA102M-25.89M-394%
Gain YTD-6.26722.082-28%
P/E Ratio12.55N/A-
Revenue996M0-
Total Cash682M27.5M2,480%
Total Debt56M52.8K106,061%
FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
22
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADEPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
63%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
37%
Advances
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 16 days ago
72%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WCPIX47.72N/A
N/A
Communication Services UltraSectorProInv
HFEAX53.33N/A
N/A
Janus Henderson European Focus A
TEMLX8.43N/A
N/A
Nuveen Emerging Markets Eq R6
DEVDX12.22N/A
N/A
Driehaus Event Driven
FIQBX28.00N/A
N/A
Fidelity Advisor Asset Manager 70% Z

EPRX and

Correlation & Price change

A.I.dvisor tells us that EPRX and CCCC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPRX and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPRX
1D Price
Change %
EPRX100%
+2.93%
CCCC - EPRX
30%
Poorly correlated
-5.06%
ETNB - EPRX
29%
Poorly correlated
-3.82%
ACAD - EPRX
28%
Poorly correlated
-1.83%
FDMT - EPRX
27%
Poorly correlated
-1.51%
ALEC - EPRX
27%
Poorly correlated
-7.50%
More